{
  "docId": "019de073-3cb6-7521-8cc2-fe64231d84c9",
  "docSlug": "d538949ee3add2afed287b359e626655",
  "documentTitle": "AN2 Therapeutics | Investor Presentation Deck | 25 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 25,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a split-layout with a company mission statement on the left and product-specific details on the right.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-3cb6-7521-8cc2-fe64231d84c9/24",
  "deckHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9",
  "deckJsonHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9.json",
  "deckAnchorHref": "/decks/019de073-3cb6-7521-8cc2-fe64231d84c9#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.3,
        "y": 0.82
      },
      "kind": "callout",
      "text": "We expect our boron chemistry expertise to drive future pipeline of differentiated compounds",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7a35c55-1143-4f01-9f24-8e88ca20f00d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.3,
        "y": 0.2
      },
      "kind": "list",
      "text": "Large market opportunity given the high unmet need; Arikayce, the only approved therapy for NTM lung disease, had 2021 WW net sales of >$189M in its third year on the market (Arikayce 2Q'22: WW $65.2M +44% Y/Y)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a78cd20-6157-45af-8c17-95deaf5c0984",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.65,
        "x": 0.3,
        "y": 0.35
      },
      "kind": "list",
      "text": "Ideal Target Product Profile: Novel mechanism of action, broad spectrum antimycobacterial activity; Convenient, once-daily oral dosing; Superior profile compared to SoC combination regimen in preclinical NTM models; Multiple Phase 1 studies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49407ce5-5739-4b5f-aa1e-e4a64822814e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.3,
        "y": 0.75
      },
      "kind": "list",
      "text": "Potential to develop epetraborole to address additional geographies and NTM indications",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77e05e4b-a865-48ad-97e7-e06b2dbb77d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.65,
        "x": 0.3,
        "y": 0.1
      },
      "kind": "list",
      "text": "Epetraborole (EBO): Pivotal phase 2/3 ready antibiotic product candidate for non-tuberculous mycobacterial (NTM) lung disease",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8449be1a-3e36-4226-82df-8006632788b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.3,
        "y": 0.6
      },
      "kind": "list",
      "text": "Phase 2/3 pivotal trial expected to support U.S. and Japan regulatory approval for treatment-refractory MAC lung disease; initiated study June 2022; topline Phase 2 data mid 2023; QIDP, Fast Track, and orphan drug designations granted in U.S.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea1106f3-8dd1-4ffb-a0ee-aaf5d8edcb6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "AN2 Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79a9893b-eeed-4ffc-82d0-71d8bfc28795",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.3,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Insmed FY 2021 10-K 2. Insmed 2Q 2022 10-Q",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afe0401f-ff47-49c4-8b93-b5ec6140b770",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "ef02a5bb-4f19-4287-bf58-a35155d31fc6",
      "evidence": "list/bullet: Phase 2/3 pivotal trial expected to support U.S. and Japan regulatory approval for treatment-refractory MAC lung disease; initiated study June 2022; topline Phase 2 data mid 2023; QIDP, Fast Track, and orpha",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}